James A. Ruggles - Concepedia

Author

James A. Ruggles

University of Colorado Boulder

Also Known As

C. L. Brand, J A Ruggles, J. A. Ruggles, J.A. Ruggles, JAMES A. RUGGLES, James A Ruggles, James A. Ruggles

Publications

1.9K

Citations

H-Index

Concepts

All Affiliations

University of Colorado Boulder Diabetes & Glandular Disease Clinic AstraZeneca (United States)Amplyx Pharmaceuticals (United States)

About

James A. Ruggles is an author at University of Colorado Boulder specializing in molecular biology, structural biology, and natural sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	105
2	Natural Sciences	3	3	307
3	Engineering	2	2	51
4	Biochemistry	2	2	293
5	Health Sciences	1	1	25

James A. Ruggles

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus Orville Kolterman, Dennis Dong Hwan Kim, Larry Z. Shen, American Journal of Health-System Pharmacy	2005	434
A Randomized Study and Open-Label Extension Evaluating the Long-Term Efficacy of Pramlintide as an Adjunct to Insulin Therapy in Type 1 Diabetes Fred W. Whitehouse, Davida Kruger, Mark Fineman, Diabetes Care	2002	258
Crystal Structure of the Oxytricha nova Telomere End Binding Protein Complexed with Single Strand DNA Martin P. Horvath, Viloya L Schweiker, Joanne M. Bevilacqua, Cell Crystal StructureBiochemistryStructural BioinformaticsNatural SciencesProtein X-ray Crystallography	1998	252
Effect of Pramlintide on Weight in Overweight and Obese Insulin‐Treated Type 2 Diabetes Patients Priscilla Hollander, David Maggs, James A. Ruggles, Obesity Research	2004	192
Adjunctive Therapy with the Amylin Analogue Pramlintide Leads to a Combined Improvement in Glycemic and Weight Control in Insulin-Treated Subjects with Type 2 Diabetes Robert E. Ratner, Laura L. Want, Mark Fineman, Diabetes Technology & Therapeutics	2002	154
Pramlintide Reduces Postprandial Glucose Excursions When Added to Regular Insulin or Insulin Lispro in Subjects With Type 1 Diabetes Christian Weyer, Alan Gottlieb, Dennis Dong Hwan Kim, Diabetes Care	2003	107
Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose‐timing study David Maggs, Mark Fineman, Jonathan Kornstein, Diabetes/Metabolism Research and Reviews	2004	78
Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial Lindsay E. Clegg, Robert C. Penland, Srinivas Bachina, Cardiovascular Diabetology	2019	77
Effects of Pramlintide on Postprandial Glucose Excursions and Measures of Oxidative Stress in Patients With Type 1 Diabetes Antonio Ceriello, Ludovica Piconi, Lisa Quagliaro, Diabetes Care	2005	75
Dimeric structure of the Oxytricha nova telomere end-binding protein α-subunit bound to ssDNA Olve B. Peersen, James A. Ruggles, Steve C. Schultz Nature Structural Biology Structural BioinformaticsGeneticsDimeric StructureMolecular BiologyMolecular Research	2002	43

Page 1